Overslaan en naar de inhoud gaan

''Our strong performance in 2018 and the first quarter of 2019 has enabled us to invest in future growth through the development of our pipeline. Today, following ethics committee approval, we are initiating our first pre-eclampsia study with RUCONEST®''

- Sijmen de Vries - CEO
Cookies: Deze website maakt gebruik van cookies. Bekijk de cookie instellingen pagina voor meer informatie Accepteren Weigeren